PL3570819T3 - Leczenie medyczne obejmujące podawanie dojelitowe edarawonu - Google Patents
Leczenie medyczne obejmujące podawanie dojelitowe edarawonuInfo
- Publication number
- PL3570819T3 PL3570819T3 PL17737775T PL17737775T PL3570819T3 PL 3570819 T3 PL3570819 T3 PL 3570819T3 PL 17737775 T PL17737775 T PL 17737775T PL 17737775 T PL17737775 T PL 17737775T PL 3570819 T3 PL3570819 T3 PL 3570819T3
- Authority
- PL
- Poland
- Prior art keywords
- edaravone
- medical treatment
- enteral administration
- enteral
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17151741 | 2017-01-17 | ||
| PCT/EP2017/067005 WO2018133957A1 (en) | 2017-01-17 | 2017-07-06 | Medical treatment comprising enteral administration of edaravone |
| EP17737775.1A EP3570819B1 (en) | 2017-01-17 | 2017-07-06 | Medical treatment comprising enteral administration of edaravone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3570819T3 true PL3570819T3 (pl) | 2021-10-25 |
Family
ID=57850912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17737775T PL3570819T3 (pl) | 2017-01-17 | 2017-07-06 | Leczenie medyczne obejmujące podawanie dojelitowe edarawonu |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10966960B2 (pl) |
| EP (1) | EP3570819B1 (pl) |
| JP (1) | JP6898027B2 (pl) |
| AU (1) | AU2017394478B2 (pl) |
| BR (1) | BR112019014712A2 (pl) |
| CA (1) | CA3050031A1 (pl) |
| DK (1) | DK3570819T3 (pl) |
| ES (1) | ES2868955T3 (pl) |
| MX (1) | MX2019008482A (pl) |
| PL (1) | PL3570819T3 (pl) |
| PT (1) | PT3570819T (pl) |
| WO (1) | WO2018133957A1 (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6898027B2 (ja) | 2017-01-17 | 2021-07-07 | ツリーウェイ ティーダブリュー００１ ビー．ブイ．Ｔｒｅｅｗａｙ ＴＷ００１ Ｂ．Ｖ． | エダラボンの腸内投与を含む医療処置 |
| US11826352B2 (en) | 2018-11-02 | 2023-11-28 | Mitsubishi Tanabe Pharma Corporation | Edaravone suspension for oral administration |
| AU2019369843A1 (en) | 2018-11-02 | 2021-05-27 | Mitsubishi Tanabe Pharma Corporation | Edaravone suspension for oral administration |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2248144T3 (es) | 2000-10-24 | 2006-03-16 | Mitsubishi Pharma Corporation | Medicamentos para tratar la esclerosis lateral amiotrofica (ela). |
| IS7278A (is) | 2001-11-26 | 2003-05-27 | Merlyn Associates, Inc. | Barkaslanga með stefnustjórnanlegum enda og stöðuhaldandi búnaði |
| CN1241565C (zh) * | 2003-04-16 | 2006-02-15 | 浙江震元制药有限公司 | 依达拉奉药物组合物及制备 |
| CN100358520C (zh) | 2003-09-11 | 2008-01-02 | 彭建华 | 具有良好稳定性的注射用依达拉奉粉针剂及其制备方法 |
| JP4988204B2 (ja) | 2004-02-09 | 2012-08-01 | 田辺三菱製薬株式会社 | 筋萎縮性側索硬化症（ａｌｓ）又はａｌｓに起因する疾患の新規治療剤 |
| CN101953832B (zh) | 2010-08-10 | 2012-02-15 | 南京师范大学 | β-环糊精包合依达拉奉的口服药物组合物及其制备方法 |
| CN102349893A (zh) * | 2011-08-19 | 2012-02-15 | 福建天泉药业股份有限公司 | 依达拉奉药物组合物 |
| EP2754440B1 (en) | 2011-09-05 | 2019-04-03 | Mitsubishi Tanabe Pharma Corporation | Medicinal agent for treating amyotrophic lateral sclerosis or preventing progression of phase of amyotrophic lateral sclerosis |
| CN103251554A (zh) | 2013-06-06 | 2013-08-21 | 南京亿华药业有限公司 | 一种稳定的依达拉奉注射液及其制备方法 |
| CN111840218B (zh) | 2016-03-16 | 2022-07-12 | 苏州澳宗生物科技有限公司 | 依达拉奉剂型 |
| JP6898027B2 (ja) | 2017-01-17 | 2021-07-07 | ツリーウェイ ティーダブリュー００１ ビー．ブイ．Ｔｒｅｅｗａｙ ＴＷ００１ Ｂ．Ｖ． | エダラボンの腸内投与を含む医療処置 |
| DK3551181T3 (da) | 2017-01-17 | 2020-11-30 | Treeway Tw001 B V | Behandling omfattende oral eller gastrisk indgivelse af edaravone |
| JP7277005B2 (ja) | 2017-07-06 | 2023-05-18 | ツリーウェイ ティーダブリュー００１ ビー．ブイ． | 酸化ストレス媒介性の神経変性障害の経口治療におけるエダラボンの使用 |
-
2017
- 2017-07-06 JP JP2019559159A patent/JP6898027B2/ja active Active
- 2017-07-06 DK DK17737775.1T patent/DK3570819T3/da active
- 2017-07-06 AU AU2017394478A patent/AU2017394478B2/en active Active
- 2017-07-06 BR BR112019014712-8A patent/BR112019014712A2/pt active Search and Examination
- 2017-07-06 MX MX2019008482A patent/MX2019008482A/es unknown
- 2017-07-06 ES ES17737775T patent/ES2868955T3/es active Active
- 2017-07-06 EP EP17737775.1A patent/EP3570819B1/en active Active
- 2017-07-06 PL PL17737775T patent/PL3570819T3/pl unknown
- 2017-07-06 PT PT177377751T patent/PT3570819T/pt unknown
- 2017-07-06 WO PCT/EP2017/067005 patent/WO2018133957A1/en active Search and Examination
- 2017-07-06 CA CA3050031A patent/CA3050031A1/en active Pending
-
2019
- 2019-07-12 US US16/510,497 patent/US10966960B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6898027B2 (ja) | 2021-07-07 |
| AU2017394478A1 (en) | 2019-08-01 |
| US20190328711A1 (en) | 2019-10-31 |
| AU2017394478B2 (en) | 2023-07-20 |
| WO2018133957A1 (en) | 2018-07-26 |
| EP3570819B1 (en) | 2021-03-03 |
| CA3050031A1 (en) | 2018-07-26 |
| JP2020506958A (ja) | 2020-03-05 |
| EP3570819A1 (en) | 2019-11-27 |
| ES2868955T3 (es) | 2021-10-22 |
| DK3570819T3 (da) | 2021-04-06 |
| BR112019014712A2 (pt) | 2020-02-18 |
| MX2019008482A (es) | 2019-11-11 |
| US10966960B2 (en) | 2021-04-06 |
| PT3570819T (pt) | 2021-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3294404A4 (en) | Medical connectors configured to receive emitters of therapeutic agents | |
| SG11201609014TA (en) | Gpc3 -targeting drug which is administered to patient responsive to gpc3-targeting drug therapy | |
| IL268127A (en) | Preparations containing adrevan for oral or gastric administration and their use for treatment | |
| EP3273955A4 (en) | TREATMENT OF RESPIRATORY DISEASES | |
| EP3253451A4 (en) | Diagnosis and treatment of chronic pain | |
| ZA201902090B (en) | Combination treatments comprising administration of imidazopyrazinones | |
| EP3275482A4 (en) | Syringe holder and medical solution administration set | |
| PL3558455T3 (pl) | Kapsułka do spożycia do leczenia zakażeń na zasadzie fototerapii | |
| EP3212170A4 (en) | Implantable medical devices for extended release of therapeutic agents | |
| HK1254855A1 (zh) | 在手術期間給患者靜脈內施用瓜氨酸 | |
| GB201507048D0 (en) | Treatment of pain | |
| PL3570819T3 (pl) | Leczenie medyczne obejmujące podawanie dojelitowe edarawonu | |
| EP3684345A4 (en) | TREATMENT OF DRUG RESISTANT GLIOMAS | |
| IL261116A (en) | A drug for the treatment of diabetic foot infections | |
| HK1225995A1 (zh) | 用於治療或緩解高齡或晚期癌症患者的藥物組合物 | |
| PL3431119T3 (pl) | Aparat do pozaustrojowego oczyszczania krwi | |
| PT3509486T (pt) | Aparelho médico para a introdução de cateteres no corpo humano | |
| ZA201904655B (en) | Treatment comprising oral or gastric administration of edaravone | |
| PT3551181T (pt) | Tratamento compreendendo a administração oral ou gástrica de edaravona | |
| IL275150A (en) | System for hypothermia treatment of a patient | |
| IL248252A0 (en) | A medicine to treat tinnitus patients | |
| IL248253A0 (en) | A medicine to treat tinnitus patients | |
| GB201805556D0 (en) | Treatment of ophthalmological conditions | |
| IL252080A0 (en) | Oral administration of drugs that are unstable or poorly absorbed | |
| GB201710382D0 (en) | Administration and dosage of Diaminophenothiazines |